Shaaban Abeer M, Kaur Tanvier, Provenzano Elena
Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2GW, UK.
Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Medicina (Kaunas). 2025 Apr 1;61(4):644. doi: 10.3390/medicina61040644.
The concept of binary classification of HER2 status has recently been challenged following the DESTINY-Breast trial data showing a clinically meaningful response to antibody-drug conjugates (ADCs) in invasive breast cancer expressing low levels of HER2. HER2-low breast cancer is defined as an immunohistochemistry (IHC) score of 1+ and 2+ without HER2 gene amplification. While HER2-low breast cancer does not represent a biological entity, it encompasses both hormone receptor-positive and triple-negative breast cancer. Differences exist between this group and HER2-null breast cancer. In this review, we provide an update on HER2-low and HER2-ultralow breast cancer, including background trial data, the evolution of HER2-low expression, current clinical guidelines, quality issues, and future directions.
在DESTINY-Breast试验数据显示，低水平HER2表达的浸润性乳腺癌对抗体-药物偶联物（ADC）有临床意义的反应之后，HER2状态的二元分类概念最近受到了挑战。HER2低表达乳腺癌被定义为免疫组织化学（IHC）评分为1+和2+且无HER2基因扩增。虽然HER2低表达乳腺癌并不代表一个生物学实体，但它包括激素受体阳性和三阴性乳腺癌。该组与HER2阴性乳腺癌之间存在差异。在这篇综述中，我们提供了关于HER2低表达和HER2超低表达乳腺癌的最新信息，包括背景试验数据、HER2低表达的演变、当前临床指南、质量问题和未来方向。
